We aimed to determine endocan and high sensitive C reactive protein (hs-CRP) levels in the serum of both ischemic and hemorrhagic stroke patients in the acute period(on the first day of the event) and to determine the role of endocan and hs-CRP levels on stroke development and prognosis by comparing these levels with those of healthy controls. Venous blood samples were taken from 45 patients who were admitted to Cumhuriyet University Hospital Neurology Department between June 1, 2018 and 2019, and volunteers, and serum endocan and hs-CRP levels were examined. The relationship of these values with arrival Glasgow Coma Score, National Institutes of Health Stroke Scale, Modified Rankin Score (MRS), 3rd month MRS values and lesion volumes on brain imaging were evaluated. Results: Although endocan levels were higher in the patient group compared to the control group, there was no statistically significant difference between the groups (p = 0.052). The hs-CRP level of the patient group was statistically higher than the control group (p <0.001). There was no statistically significant correlation between endocan and hs-CRP levels in both cases and control and patient groups (respectively r = 0.108 and p = 0.312; r = 0.262 and p = 0.082; r=-0.127 ve p=0.405). No statistically significant correlation was observed between endocan measurements and respectively age, biochemical measurements, scorsal data and lesion volume in patient group (p> 0.05). Based on our data, while the levels of hs-CRP examined in the acute period are a good indicator in determining stroke severity, prognosis and degree of disability in both acute and chronic periods in patients with ischemic cerebrovascular disease and intracerebral hemorrhage regardless of presence of chronic disease; endocan levels evaluated in the acute period are not related with stroke subtype, stroke etiology, lesion volume.
Stroke, Inflammation, Endocan, Hs-CRP